Tapewire

Nasdaq · USD

NBIX

NEUROCRINE BIOSCIENCES INC

Export transactions ↓
Tapewire entity
2655
SEC CIK
0000914475
Parsed reports
676

Last 12 months

Inside the activity.

0 purchase rows · 40 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202504
Dec 202504
Jan 202602
Feb 202600
Mar 202600
Apr 202600
May 202606
Jun 2026015
Jul 202606
Aug 202600
Sep 202603
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 02, 2017 Filed Oct 3, 2017 23:14 UTC
OBrien Christopher FlintChief Medical Officer
SaleCommon Stock 6,925 $61.04 $422,702.00
Disclosure

SEC source: 0001209191-17-055457 · doc4.xml · nonDerivative · entry 2

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,973

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $60.40 to $61.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
October 02, 2017 Filed Oct 3, 2017 23:14 UTC
OBrien Christopher FlintChief Medical Officer
Exercise / conversionCommon Stock 6,925 $8.65 $59,901.25
Disclosure

SEC source: 0001209191-17-055457 · doc4.xml · nonDerivative · entry 1

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,898

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Gano KyleChief Business Development Off
Exercise / conversionStock Option · Derivative 4,607 $8.65 Strike: $8.65 $39,850.55
Disclosure

SEC source: 0001209191-17-052021 · doc4.xml · derivative · entry 3

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,390

Underlying: Common Stock · 4,607 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Gano KyleChief Business Development Off
SaleCommon Stock 4,607 $60.00 $276,420.00
Disclosure

SEC source: 0001209191-17-052021 · doc4.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,246

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Gano KyleChief Business Development Off
Exercise / conversionCommon Stock 4,607 $8.65 $39,850.55
Disclosure

SEC source: 0001209191-17-052021 · doc4.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:59 UTC
Lippoldt DarinChief Legal Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 100 $18.15 Strike: $18.15 $1,815.00
Disclosure

SEC source: 0001209191-17-052022 · doc4.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,139

Underlying: Common Stock · 100 shares

Expires 2024-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents option which vested 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:59 UTC
Lippoldt DarinChief Legal Officer
SaleCommon Stock 100 $60.00 $6,000.00
Disclosure

SEC source: 0001209191-17-052022 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,157

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:59 UTC
Lippoldt DarinChief Legal Officer
Exercise / conversionCommon Stock 100 $18.15 $1,815.00
Disclosure

SEC source: 0001209191-17-052022 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,257

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionIncentive Stock Option · Derivative 313 $19.59 Strike: $19.59 $6,131.67
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · derivative · entry 8

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,665

Underlying: Common Stock · 313 shares

Expires 2024-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options granted January 16, 2014 and vests monthly over four years.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 10,937 $19.59 Strike: $19.59 $214,255.83
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · derivative · entry 7

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,085

Underlying: Common Stock · 10,937 shares

Expires 2024-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options granted January 16, 2014 and vests monthly over four years.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionIncentive Stock Option · Derivative 2,207 $8.65 Strike: $8.65 $19,090.55
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · derivative · entry 6

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,830

Underlying: Common Stock · 2,207 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options granted January 10, 2013 and vested monthly over four years.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 12,793 $8.65 Strike: $8.65 $110,659.45
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · derivative · entry 5

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,170

Underlying: Common Stock · 12,793 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options granted January 10, 2013 and vested monthly over four years.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
SaleCommon Stock 11,250 $60.00 $675,000.00
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · nonDerivative · entry 4

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,601

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionCommon Stock 11,250 $19.59 $220,387.50
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · nonDerivative · entry 3

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
SaleCommon Stock 15,000 $60.00 $900,000.00
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · nonDerivative · entry 2

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,601

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
September 06, 2017 Filed Sep 8, 2017 18:58 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionCommon Stock 15,000 $8.65 $129,750.00
Disclosure

SEC source: 0001209191-17-052020 · doc4.xml · nonDerivative · entry 1

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 06, 2017 Filed Oct 3, 2017 23:13 UTC
Gano KyleChief Business Development Off
Exercise / conversionStock Option · Derivative 20,393 $8.65 Strike: $8.65 $176,399.45
Disclosure

SEC source: 0001209191-17-055452 · doc4.xml · derivative · entry 3

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 20,393 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years.

Read SEC document
September 06, 2017 Filed Oct 3, 2017 23:13 UTC
Gano KyleChief Business Development Off
SaleCommon Stock 20,393 $60.00 $1,223,580.00
Disclosure

SEC source: 0001209191-17-055452 · doc4.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,246

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
September 06, 2017 Filed Oct 3, 2017 23:13 UTC
Gano KyleChief Business Development Off
Exercise / conversionCommon Stock 20,393 $8.65 $176,399.45
Disclosure

SEC source: 0001209191-17-055452 · doc4.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 05, 2017 Filed Sep 7, 2017 21:55 UTC
OBrien Christopher FlintChief Medical Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 52,817 $8.66 Strike: $8.66 $457,395.22
Disclosure

SEC source: 0001209191-17-051944 · doc4.xml · derivative · entry 3

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,299

Underlying: Common Stock · 52,817 shares

Expires 2022-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted January 12, 2012 and vested in 36 equal monthly installments.

Read SEC document
September 05, 2017 Filed Sep 7, 2017 21:55 UTC
OBrien Christopher FlintChief Medical Officer
SaleCommon Stock 52,817 $57.50 $3,036,977.50
Disclosure

SEC source: 0001209191-17-051944 · doc4.xml · nonDerivative · entry 2

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,973

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $57.50 to $57.52. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 05, 2017 Filed Sep 7, 2017 21:55 UTC
OBrien Christopher FlintChief Medical Officer
Exercise / conversionCommon Stock 52,817 $8.66 $457,395.22
Disclosure

SEC source: 0001209191-17-051944 · doc4.xml · nonDerivative · entry 1

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,790

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:29 UTC
Grigoriadis Dimitri E.Chief Research Officer
Exercise / conversionIncentive Stock Option · Derivative 15,354 $5.76 Strike: $5.76 $88,439.04
Disclosure

SEC source: 0001209191-17-048696 · doc4.xml · derivative · entry 3

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,354 shares

Expires 2021-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:29 UTC
Grigoriadis Dimitri E.Chief Research Officer
SaleCommon Stock 15,354 $55.00 $844,470.00
Disclosure

SEC source: 0001209191-17-048696 · doc4.xml · nonDerivative · entry 2

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,691

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:29 UTC
Grigoriadis Dimitri E.Chief Research Officer
Exercise / conversionCommon Stock 15,354 $5.76 $88,439.04
Disclosure

SEC source: 0001209191-17-048696 · doc4.xml · nonDerivative · entry 1

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:30 UTC
Lippoldt DarinChief Legal Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 5,000 $18.15 Strike: $18.15 $90,750.00
Disclosure

SEC source: 0001209191-17-048697 · doc4.xml · derivative · entry 3

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,239

Underlying: Common Stock · 5,000 shares

Expires 2024-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:30 UTC
Lippoldt DarinChief Legal Officer
SaleCommon Stock 5,000 $55.00 $275,000.00
Disclosure

SEC source: 0001209191-17-048697 · doc4.xml · nonDerivative · entry 2

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,157

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
August 09, 2017 Filed Aug 14, 2017 16:30 UTC
Lippoldt DarinChief Legal Officer
Exercise / conversionCommon Stock 5,000 $18.15 $90,750.00
Disclosure

SEC source: 0001209191-17-048697 · doc4.xml · nonDerivative · entry 1

Lippoldt Darin · CIK 0001504783 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionIncentive Stock Option · Derivative 2,726 $8.66 Strike: $8.66 $23,607.16
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · derivative · entry 8

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 2,726 shares

Expires 2022-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted January 12, 2012 and vested in 36 equal monthly installments.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionNon Qualified Stock Option · Derivative 17,274 $8.66 Strike: $8.66 $149,592.84
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · derivative · entry 7

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,726

Underlying: Common Stock · 17,274 shares

Expires 2022-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted January 12, 2012 and vested in 36 equal monthly installments.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionIncentive Stock Option · Derivative 5,071 $5.76 Strike: $5.76 $29,208.96
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · derivative · entry 6

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 5,071 shares

Expires 2021-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionNon Qualified Stock Option · Derivative 19,929 $5.76 Strike: $5.76 $114,791.04
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · derivative · entry 5

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,071

Underlying: Common Stock · 19,929 shares

Expires 2021-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
SaleCommon Stock 20,000 $50.00 $1,000,000.00
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · nonDerivative · entry 4

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,601

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionCommon Stock 20,000 $8.66 $173,200.00
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · nonDerivative · entry 3

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
SaleCommon Stock 2,500 $50.00 $125,000.00
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · nonDerivative · entry 2

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,601

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
August 04, 2017 Filed Aug 8, 2017 21:44 UTC
Bozigian Haig P.Chief Development Officer
Exercise / conversionCommon Stock 25,000 $5.76 $144,000.00
Disclosure

SEC source: 0001209191-17-048144 · doc4.xml · nonDerivative · entry 1

Bozigian Haig P. · CIK 0001423837 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,601

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 27, 2017 Filed Jul 31, 2017 20:29 UTC
OBrien Christopher FlintChief Medical Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 8,734 $8.65 Strike: $8.65 $75,549.10
Disclosure

SEC source: 0001209191-17-046685 · doc4.xml · derivative · entry 3

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,266

Underlying: Common Stock · 8,734 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option granted January 10, 2013 and vested over 4 years.

Read SEC document
July 27, 2017 Filed Jul 31, 2017 20:29 UTC
OBrien Christopher FlintChief Medical Officer
SaleCommon Stock 8,734 $50.00 $436,700.00
Disclosure

SEC source: 0001209191-17-046685 · doc4.xml · nonDerivative · entry 2

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,973

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document
July 27, 2017 Filed Jul 31, 2017 20:29 UTC
OBrien Christopher FlintChief Medical Officer
Exercise / conversionCommon Stock 8,734 $8.65 $75,549.10
Disclosure

SEC source: 0001209191-17-046685 · doc4.xml · nonDerivative · entry 1

OBrien Christopher Flint · CIK 0001343124 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,707

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 23, 2017 Filed May 24, 2017 20:13 UTC
Grigoriadis Dimitri E.Chief Research Officer
SaleCommon Stock 10,000 $53.39 $533,900.00
Disclosure

SEC source: 0001209191-17-034910 · doc4.xml · nonDerivative · entry 1

Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,691

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $53.01 to $53.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:37 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038638 · doc4.xml · derivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:36 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038636 · doc4.xml · derivative · entry 1

Sandrock Alfred · CIK 0001577061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:35 UTC GrantStock Option · Derivative 18,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038634 · doc4.xml · derivative · entry 1

RASTETTER WILLIAM H · CIK 0001205903 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:33 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038633 · doc4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:32 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038632 · doc4.xml · derivative · entry 1

Nevinny Corinne H · CIK 0001182467 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:31 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038631 · doc4.xml · derivative · entry 1

MORROW GEORGE J · CIK 0001068754 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:30 UTC GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038629 · doc4.xml · derivative · entry 1

MOLLICA JOSEPH A · CIK 0001126489 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 22, 2017 Filed Jun 8, 2017 22:29 UTC
LYONS GARY ADirector
GrantStock Option · Derivative 15,000 $0.00 Strike: $53.64 $0.00
Disclosure

SEC source: 0001209191-17-038628 · doc4.xml · derivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-22

F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017.

Read SEC document
May 19, 2017 Filed May 23, 2017 20:34 UTC
Lloyd-Smith MalcolmChief Regulatory Officer
Exercise / conversionNon-Qualified Stock Option · Derivative 4,980 $15.45 Strike: $15.45 $76,941.00
Disclosure

SEC source: 0001209191-17-034632 · doc4.xml · derivative · entry 6

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,040

Underlying: Common Stock · 4,980 shares

Expires 2024-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (10/1/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 10/1/2018.

Read SEC document
May 19, 2017 Filed May 23, 2017 20:34 UTC
Lloyd-Smith MalcolmChief Regulatory Officer
SaleCommon Stock 4,980 $54.00 $268,920.00
Disclosure

SEC source: 0001209191-17-034632 · doc4.xml · nonDerivative · entry 4

Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,017

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.